GGrantIndex
← Leaderboards

Howard Trachtman

Long Island Jewish Medical Center

$5,969,201
Attributed
$7,759,674
Total exposure
20
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $839.1K · FY200520
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$7,759,674 · 20

By mechanism

R01$3,879,185 · 3
R33$1,476,477 · 1
UC1$929,151 · 1
R21$839,890 · 2
M01$364,225 · 12
R56$270,746 · 1

Top collaborators

Most similar at Long Island Jewish Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsClinical ResearchFundingKidneyResearch PersonnelKidney DiseasesAdultChildChildhoodResourcesMedicalUnited States National Institutes Of HealthDesignPerformanceEtiologyFocal Segmental GlomerulosclerosisGrantComputer Retrieval Of Information On Scientific Projects DatabaseResponseRenal FunctionInstitutionHuman SubjectEnd Stage Renal FailureProteinuria

Grant awards (32)

Developmental Origins of Kidney Function in Early Life and Environmental Risks$720,375
R01 · FY2020 · ES
Environmental Oxidant Stressors in Pediatric Chronic Kidney Disease - Resubmissio$636,758
R01 · FY2018 · DK
Environmental Oxidant Stressors in Pediatric Chronic Kidney Disease - Resubmissio$636,758
R01 · FY2017 · DK
Environmental Oxidant Stressors in Pediatric Chronic Kidney Disease - Resubmissio$622,884
R01 · FY2015 · DK
Environmental Oxidant Stressors in Pediatric Chronic Kidney Disease - Resubmissio$558,053
R01 · FY2014 · DK
Novel Therapies for Resistant FSGS$1
R33 · FY2011 · DK · contact PI
FSGS Cohort Study$270,746
R56 · FY2010 · DK
Novel Therapies for Resistant FSGS$725,182
R33 · FY2009 · DK · contact PI
CLINICAL TRIAL: TREATMENT WITH (F6-3019) FOR FOCAL GLOMERULOSCLEROSIS$335
M01 · FY2009 · RR · contact PI
Novel Therapies for Resistant FSGS$751,294
R33 · FY2008 · DK · contact PI
CLINICAL TRIAL: NOVEL THERAPY FOR RESISTANT FOCAL SEGMENTAL GLOMERULOSCLEROSIS$73,065
M01 · FY2008 · RR · contact PI
TREATMENT WITH HUMAN MONOCLONAL ANTIBODY TO CONNECTIVE TISSUE GROWTH FACTOR (FG-$6,445
M01 · FY2008 · RR · contact PI
CATHETER-RELATED INFECTIONS IN PEDIATRIC DIALYSIS PATIENTS: POTENTIAL ROLE OF$5,525
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES$2,762
M01 · FY2008 · RR · contact PI
International Network and Registry for TMA$211,320
R21 · FY2007 · DK · contact PI
NOVEL THERAPY FOR RESISTANT FOCAL SEGMENTAL GLOMERULOSCLEROSIS$50,672
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES$3,417
M01 · FY2007 · RR · contact PI
Novel Therapies for Resistant FSGS$195,300
R21 · FY2006 · DK · contact PI
International Network and Registry for TMA$193,350
R21 · FY2006 · DK · contact PI
A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES$18,527
M01 · FY2006 · RR · contact PI
NOVEL THERAPY FOR RESISTANT FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)$10,885
M01 · FY2006 · RR · contact PI
CATHETER-RELATED INFECTIONS IN PEDIATRIC DIALYSIS PATIENTS: POTENTIAL ROLE OF$771
M01 · FY2006 · RR · contact PI
Novel Therapies for Resistant FSGS$239,920
R21 · FY2005 · DK
A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES$51,676
M01 · FY2005 · RR
CATHETER-RELATED INFECTIONS IN PEDIATRIC DIALYSIS PATIENTS: POTENTIAL ROLE OF$10,934
M01 · FY2005 · RR
Human monoclonal antibody therapy for HUS$929,151
UC1 · FY2004 · AI
Pilot--Mycophenolate Mofetil in Congenital Uropathies$123,815
M01 · FY2004 · RR
Catheter-related infections in pediatric dialysis$5,396
M01 · FY2004 · RR
MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS$8,040
R01 · FY2003 · DK
MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS$248,052
R01 · FY2002 · DK
MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS$419,603
R01 · FY2000 · DK
MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS$28,662
R01 · FY2000 · DK